

NOTIFICATION AND FORM FOR ADVANCE VOTING

The notification and form should be at Xbrane Biopharma AB disposal no later than 28 April 2025

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Xbrane Biopharma AB, reg. no. 556749-2375 at the annual general meeting on 5 May 2025. The voting right is exercised in accordance with the below marked voting options.

Name of shareholder	Personal ID number / date of birth/Registration number
Telephone number	E-mail
Place and date	
Signature*	
Clarification of signature	

*In case of signing on behalf of a legal entity, the name of the signatory shall be printed next to the signature and an up-to-date certificate of registration (or a similar document) shall be attached to the proxy form.

Instructions to vote in advance:

Complete the shareholder information above

- Select the preferred voting options below.
- Print, sign and send the form in the original to Baker McKenzie Advokatbyrå, Attn: Simon Olofsson, Box 180, 101 23 Stockholm. A completed and signed form may also be submitted electronically and shall, in that case, be sent to simon.olofsson@bakermckenzie.com.
- If the shareholder is a legal entity, a copy of a registration certificate or a corresponding document for the legal entity shall be enclosed together with the form. The same applies if the shareholder votes in advance by proxy.
- Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this is included in the notice convening the meeting.
- If a shareholder does not intend to exercise its voting right by way of advance voting, the form for advance voting should not be submitted.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorization documentation, shall be provided to Xbrane Biopharma AB no later than on 28 April 2025. An advance vote can be withdrawn up to and including 28 April 2025 by contacting the company via simon.olofsson@bakermckenzie.com. Thereafter, an advance vote can only be withdrawn if the shareholder is present, in person or by proxy, at the annual general meeting.

For complete proposals for the items on the agenda, kindly refer to the notice convening the meeting a on Xbrane Biopharma AB's website, www.xbrane.com.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual general meeting in Xbrane Biopharma AB on 5 May 2025

The options below comprise the proposals submitted to the general meeting which are included in the notice convening the annual general meeting.

1. Opening of the meeting and election of chairman of the general meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
3. Approval of the proposed agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Examination of whether the general meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
7.a. Resolution regarding adoption of income statement and balance sheet and the group income statement and the group balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
7.b. Resolution regarding the profit or loss of the Company in accordance with the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
7.c. Resolution regarding discharge from liability of the board of directors and the CEO
7.c. i. Anders Tullgren (chairman of the board of directors) Yes <input type="checkbox"/> No <input type="checkbox"/>
7.c. ii. Eva Nilsagård (director) Yes <input type="checkbox"/> No <input type="checkbox"/>
7.c. iii. Mats Thorén (director) Yes <input type="checkbox"/> No <input type="checkbox"/>
7.c iv. Kirsti Gjellan (director) Yes <input type="checkbox"/> No <input type="checkbox"/>
7.c v. Kristoffer Bissessar (director) Yes <input type="checkbox"/> No <input type="checkbox"/>
8. Determining the number of directors and auditors
8.a. Number of directors Yes <input type="checkbox"/> No <input type="checkbox"/>
8.b. Number of auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Determining the fees for the board of directors and the auditor
9.a. Fees to the board of directors Yes <input type="checkbox"/> No <input type="checkbox"/>

9.b. Fees to the auditor Yes <input type="checkbox"/> No <input type="checkbox"/>
10. Election of the board of directors and auditor
10.a. Anders Tullgren, chairman of the board of directors (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.b. Eva Nilsagård, director (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.c. Mats Thorén, director (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.d. Kirsti Gjellan, director (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.e Kristoffer Bissessar, director (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
10.f. PricewaterhouseCoopers AB, auditor (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11. Resolution regarding adoption of principles for the nomination committee Yes <input type="checkbox"/> No <input type="checkbox"/>
12. Resolution regarding approval of the remuneration report Yes <input type="checkbox"/> No <input type="checkbox"/>
13. Resolution regarding adoption of guidelines for remuneration to senior executives Yes <input type="checkbox"/> No <input type="checkbox"/>
14. Resolution regarding authorization for the board of directors to issue shares, warrants and/or convertibles Yes <input type="checkbox"/> No <input type="checkbox"/>